Insmed Q3 revenue tops $524 million; Brinsupri, Arikayce guidance raised, Japan launch underway

Insmed Incorporated reported third-quarter 2026 financial results and a business update on October 29, 2026. Total company revenues reached $524.4 million for the third quarter of 2026, with Brinsupri revenues of $400.1 million, reflecting 29% growth over the second quarter of 2026, and Arikayce revenues of $124.4 million, reflecting 9% growth over the third quarter of 2025.¹

On regulatory progress, in August 2026 Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI Tablets 25 mg (brensocatib hydrate) for non-cystic fibrosis bronchiectasis in adults and pediatric patients 12 years and older, and Insmed launched the product in Japan in October 2026 as the first and only MHLW-approved treatment for NCFB.¹ Separately, in September 2026 the FDA accepted Insmed's Supplemental New Drug Application for ARIKAYCE in Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen, granting Priority Review with a target action date of January 28, 2027.¹ Insmed plans to submit data from the Phase 3 ENCORE study to Japan's Pharmaceuticals and Medical Devices Agency in the fourth quarter of 2026 to support potential ARIKAYCE label expansion to all patients with MAC lung disease.¹

In the TPIP program, three Phase 3 studies have been initiated. Insmed has enrolled more than 35% of patients in the Phase 3 PALM-ILD study in pulmonary hypertension associated with interstitial lung disease and expects to complete enrollment in the first half of 2028.¹ The company enrolled its first patient in the Phase 3 PALM-PAH study in July 2026 and initiated the Phase 3 PALM-PPF study in September 2026.¹ Insmed continues to anticipate initiating a Phase 3 study of TPIP in idiopathic pulmonary fibrosis in the first half of 2027¹, which would bring the program to four indications, as referenced by CEO Will Lewis in discussing the company's "Phase 3 TPIP programs across four large indications."

On guidance, the company raised its full-year 2026 revenue guidance for BRINSUPRI to $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion, and for ARIKAYCE to $460 million to $470 million, from $450 million to $470 million.¹ As of September 30, 2026, Insmed had cash, cash equivalents, and marketable securities totaling approximately $1.1 billion.¹